GlassScriptPhysician profile
John M Digrazia
NPI 1376578765
$2,060.68
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $320 · 2021: $677 · 2022: $338.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $388.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $192.83 | 2019-2021 | |
| Abiomed | $148.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $144.71 | 2019-2022 | |
| Amgen INC. | $137.58 | 2019-2022 | |
| Pfizer INC. | $106.99 | 2019-2022 | |
| Abbott Laboratories | $97.92 | 2020-2021 | |
| Esperion Therapeutics, INC. | $66.91 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $64.06 | 2019 | |
| Impulse Dynamics (USA) INC. | $62.33 | 2022 | |
| Cardiovascular Systems INC. | $46.04 | 2022 | |
| Boston Scientific Corporation | $44.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.02 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.66 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $33.73 | 2019-2021 | |
| Amarin Pharma, INC. | $29.51 | 2020-2021 | |
| Genzyme Corporation | $22.20 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.53 | 2021 | |
| Bardy Diagnostics, INC. | $20.31 | 2020 | |
| Lundbeck LLC | $20.28 | 2019 | |
| Amryt Pharma Holdings LTD | $17.92 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.61 | 2022 | |
| Vifor Pharma, INC. | $16.42 | 2019 | |
| Cardiva Medical, INC. | $15.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.45 | 2019 | |
| Itamar Medical INC | $11.98 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Digrazia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.